TORISEL
Drug
PFIZER INC.
Total Payments
$3.7M
Transactions
203
Doctors
95
Companies
2
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2023 | $330.00 | 1 | 1 |
| 2022 | $73,050 | 1 | 0 |
| 2020 | $741,943 | 4 | 1 |
| 2019 | $182,913 | 18 | 1 |
| 2018 | $2.3M | 47 | 1 |
| 2017 | $412,114 | 132 | 91 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $3.7M | 104 | 99.6% |
| Consulting Fee | $14,400 | 1 | 0.4% |
| Food and Beverage | $947.58 | 98 | 0.0% |
Payments by Type
Research
$3.7M
104 transactions
General
$15,348
99 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| TORISEL NCI CRADA CLINICAL DEVELOPMENT OF CCI799 | PFIZER INC. | $1.6M | 0 |
| A RANDOMIZED PHASE III STUDY OF VINCRISTINE DACTINOMYCIN CYCLOPHOSPHAMIDE VAC ALTERNATING WITH VINCRISTINE AND IRINOTECAN VI VERSUS VACVI PLUS TEMSIROLIMUS TEM IN PATIENTS WITH INTERMEDIATE RISK IR RHABDOMYOSARCOMA RMS | PFIZER INC. | $707,836 | 0 |
| MASTER TORISEL NCI CRADA CLINICAL DEVELOPMENT OF CCI799 | PFIZER INC. | $515,415 | 0 |
| T2014001 A PHASE I TRIAL OF TEMSIROLIMUS CCI779 PFIZER INC IN COMBINATION WITH ETOPOSIDE AND CYCLOPHOSPHAMIDE IN CHILDREN WITH RELAPSED ACUTE LYMPHOBLASTIC LEUKEMIA AND NONHODGKINS LYMPHOMA | PFIZER INC. | $508,533 | 0 |
| PHASE II TRIAL OF TEMSIROLIMUS AND PERIFOSINE IN RECURRENT GLIOBLASTOMA | PFIZER INC. | $214,275 | 0 |
| WS1352529 T2014001 A PHASE I TRIAL OF TEMSIROLIMUS CCI779 PFIZER INC IN COMBINATION WITH ETOPOSIDE AND CYCLOPHOSPHAMIDE IN CHILDREN WITH RELAPSED ACUTE LYMPHOBLASTIC LEUKEMIA AND NONHODGKINS LYMPHOMA | PFIZER INC. | $107,140 | 0 |
| A RANDOMIZED PHASE 4 STUDY COMPARING 2 INTRAVENOUS TEMSIROLIMUS TEMSR REGIMENS IN SUBJECTS WITH RELAPSED REFRACTORY MANTLE CELL LYMPHOMA | PFIZER INC. | $48,868 | 0 |
| MASTERNCI CTA SUTENT CLINICAL TRIAL PROGRAM WITH THE CANCER THERAPY EVALUATION PROGRAM | PFIZER INC. | $6,940 | 0 |
| PHASE 3B RANDOMIZED OPENLABEL STUDY OF BEVACIZUMAB TEMSIROLIMUS VS BEVACIZUMAB INTERFERONALFA AS FIRSTLINE TREATMENT IN SUBJECTS WITH ADVANCED RENAL CELL CARCINOMA | PFIZER INC. | $1,350 | 0 |
| TEMSIROLIMUS CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $330.00 | 1 |
Top Doctors Receiving Payments for TORISEL — Page 4
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| , M.D | Internal Medicine | Boca Raton, FL | $6.28 | 1 |
| , MD | Hematology & Oncology | Delray Beach, FL | $6.28 | 1 |
| , MD | Hematology & Oncology | Delray Beach, FL | $6.28 | 1 |
| , MD | Internal Medicine | Provo, UT | $5.67 | 1 |
| , M.D., FACP | Hematology & Oncology | Fort Lauderdale, FL | $3.05 | 2 |
| Waris Waris | Internal Medicine | Logan, WV | $2.98 | 1 |
| , M.D | Hematology | Lake Worth, FL | $1.32 | 1 |
| , D.O | Medical Oncology | Wellington, FL | $1.32 | 1 |
| , MD | Hematology & Oncology | Lake Worth, FL | $1.11 | 1 |
| , M.D | Medical Oncology | Palm Beach Gardens, FL | $0.98 | 1 |
| , M.D | Hematology & Oncology | Tamarac, FL | $0.76 | 1 |
| , M.D | Hematology & Oncology | Tamarac, FL | $0.76 | 1 |
| , M.D | Hematology | Asheville, NC | $0.76 | 1 |
| , M.D | Medical Oncology | West Palm Beach, FL | $0.58 | 1 |
| , M.D | Internal Medicine | Cleveland, MS | $0.21 | 1 |
| , D.O | Family Medicine | Cleveland, MS | $0.21 | 1 |
| Michael Montesi | — | Cleveland, MS | $0.21 | 1 |
| , MD | Family Medicine | Cleveland, MS | $0.21 | 1 |
| , M.D | Family Medicine | Cleveland, MS | $0.21 | 1 |
| , D.O | Family Medicine | Cleveland, MS | $0.21 | 1 |
| , MD | Family Medicine | Cleveland, MS | $0.21 | 1 |
Ad
Manufacturing Companies
- PFIZER INC. $3.7M
- PFIZER PHARMACEUTICALS LLC $116.26
Product Information
- Type Drug
- Total Payments $3.7M
- Total Doctors 95
- Transactions 203
About TORISEL
TORISEL is a drug associated with $3.7M in payments to 95 healthcare providers, recorded across 203 transactions in the CMS Open Payments database. The primary manufacturer is PFIZER INC..
Payment data is available from 2017 to 2023. In 2023, $330.00 was paid across 1 transactions to 1 doctors.
The most common payment nature for TORISEL is "Unspecified" ($3.7M, 99.6% of total).
TORISEL is associated with 10 research studies, including "TORISEL NCI CRADA CLINICAL DEVELOPMENT OF CCI799" ($1.6M).